

E-Filed

Date of Deposit: January 22, 2010

Attorney Docket No. 27331-501CIP2A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Francisco Sanchez-Madrid Confirmation No.: 1583
SERIAL NUMBER: 10/770,639 EXAMINER : SKELDING, ZACHARY S
FILING DATE: February 2, 2004 ART UNIT : 1793
FOR: IMMUNE REGULATION BASED ON THE TARGETING OF EARLY ACTIVATION
MOLECULES

Mail Stop AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached PTO Form SB/08(a) in the above-identified application, copies of which are submitted herewith.

This Information Disclosure Statement is being filed after the filing of a Request for Continued Examination (RCE) and the mailing date of the non-final Office Action on the merits, but before the mailing date of either a final action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311. Each item of this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement. Accordingly, no fee is believed due.

Pursuant to 37 C.F.R. §1.704(d), each item of information in this Information Disclosure Statement was first cited in a communication from a foreign patent office for counterpart European Application No. 04707410.9, which was communicated to Applicants' U.S. Attorneys on January 11, 2010. As such this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this Information Disclosure Statement.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the

APPLICANT: **Francisco Sanchez-Madrid**
U.S.S.N.: **10/770,639**

present claims. It is also respectfully requested that the Examiner initial, sign and date, and return a copy of the signed PTO Form SB/08(a) with the next U.S. PTO communication, to evidence that the cited information has been fully considered by the U.S. Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. **50-0311**, Reference No. **27331-501CIP2A**.

Respectfully submitted,

/Sheridan K. Snedden/
Cynthia A. Kozakiewicz, Reg. No. 42,764
Sheridan K. Snedden, Reg. No. 55,998
Attorneys for Applicants
MINTZ, LEVIN
Tel: (617) 542-6000
Fax: (617) 542-2241
Customer no.: 30623

Dated: January 22, 2010